Why Investors Should Care About MindMed’s LSD Trial for Anxiety
MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
MindMed
5 Most Important Psychedelic Clinical Trials in 2022
Here’s why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.
My Favorite Psychedelic Stocks: Part 1
Our resident Psychedelic Investor details five companies he thinks are in strong position to win the psychedelic medicine race.
4 Tips for Investing in Psychedelic Stocks During a Market Downturn
Friendly advice for responsibly managing speculative bets on psychedelic stocks that may rise like a phoenix or burn to the ground.
Psychedelic Business Spotlight – February 4
Levitee Labs Announces Interim CEO and Board of Directors Shuffle…
2021: A Year in Review for the Psychedelics Business
Our resident Psychedelic Investor looks back at some of this growing industry’s biggest moments and how they may shape the business in 2022.
Psychedelic Business Spotlight – December 24
This week in psychedelic business news: FDA green lights a new psilocybin study; MindMed commences LSD treatment for ADHD; Sage Institute shuffles leadership.
Psychedelic Business Spotlight – December 17
This week in psychedelic business news: Cybin steps closer to a new patent; MindMed appoints new CEO; MAPS and Wesana Health resume negotiations.
Compass Pathways Study Finds SSRI Drugs Did Not Impede Psilocybin’s Therapeutic Effect
Chief Medical Officer Guy Goodwin calls study “a strong signal that COMP360 psilocybin therapy could be an adjunctive treatment to SSRI antidepressant as well as a monotherapy.”
New Study Suggests SSRI Drugs Can Be Used Safely with Psilocybin to Treat Depression
“If the results are confirmed in subsequent studies … antidepressants may no longer need to be stopped for psilocybin treatment,” says MindMed Executive President Dr. Miri Halperin Wernli.
End of content
End of content